Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 90 Breast Neoplasms 87 Carcinoma, Non-Small-Cell Lung 33 Triple Negative Breast Neoplasms 22 Squamous Cell Carcinoma of Head and Neck 19 Neoplasms 18 Neoplasm Metastasis 18 Ovarian Neoplasms 17 Stomach Neoplasms 15 Lung Neoplasms 13 Head and Neck Neoplasms 11 Esophageal Squamous Cell Carcinoma 10 Esophageal Neoplasms 10 Cholangiocarcinoma 10 Recurrence 9 Melanoma 8 Small Cell Lung Carcinoma 7 Sarcoma 7 Pancreatic Adenocarcinoma 7 Inflammatory Breast Neoplasms 7 Breast Neoplasms, Male 7 Adenocarcinoma 7 Prostatic Neoplasms 6 Fallopian Tube Neoplasms 6 Urinary Bladder Neoplasms 5 Carcinoma, Ovarian Epithelial 5 Biliary Tract Neoplasms 5 Uterine Cervical Neoplasms 4 Gallbladder Neoplasms 4 Carcinoma, Ductal, Breast 4

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × Albumin-Bound Paclitaxel × Clear all

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡